Such attempt follows the successful model of population-based screening for the founder HEXA variants associated with Tay-Sachs disease in the Ashkenazi Jewish population, which has successfully reduced its incidence by 90% [26]. This evidence concerns the gene HEXA and Tay-Sachs disease.